GENELUX CorpGNLX
Price (close)
$2.43
Market cap
$109.6M
P/E
—
Revenue (TTM)
$8,000
Net income
-$35.6M
Dividend yield
—
1-year total return
-42.3%
Net margin
—
Revenue growth
—
Debt / equity
—
What GENELUX Corp does.
is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic viral immunotherapies for patients
suffering from aggressive and/or difficult-to-treat tumor types. Our clinical and preclinical product candidates are intended to selectively
kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Importantly, our oncolytic immunotherapy
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $11.1M | $170,000 | $8,000 | $8,000 |
| Net income | — | — | -$5.2M | -$28.3M | -$29.9M | -$32.1M |
| Free cash flow | — | — | -$3.6M | -$21.3M | -$21.6M | -$26.4M |
More on GNLX.
- GENELUX Corp summary
- GENELUX Corp financial statements
- GENELUX Corp key metrics
- GENELUX Corp health scores and style box
- GENELUX Corp earnings
- GENELUX Corp dividends
- GENELUX Corp valuation
- GENELUX Corp ownership and insiders
- GENELUX Corp peers
Figures from GENELUX Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.